SpineGuard Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Pierre Jérôme

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	15.8yrs
CEO ownership	n/a
Management average tenure	15.8yrs
Board average tenure	12yrs

Recent management updates

Recent updates

CEO

Pierre Jérôme

15.8yrs

Tenure

€194,919

Compensation

Mr. Pierre Jérôme co-founded SpineGuard SA in January 2009 and has been its Chairman of the Board since March 14, 2018 and also serves as its Chief Executive Officer since February 13, 2020. Mr. Jérôme ser...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pierre Jérôme	Co-Founder	15.8yrs	€194.92k	no data
Stéphane Bette	Co-Founder	15.8yrs	€155.52k	no data
Maurice Bourlion	Co-Inventor & Director	no data	no data	no data
Anne-Charlotte Millard	Chief Financial Officer	1.4yrs	no data	no data
Patricia Lempereur	Vice President of International Sales & Global Marketing	no data	no data	no data

15.8yrs

Average Tenure

Experienced Management: 6W5's management team is seasoned and experienced (15.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pierre Jérôme	Co-Founder	15yrs	€194.92k	no data
Stéphane Bette	Co-Founder	7yrs	€155.52k	no data
Maurice Bourlion	Co-Inventor & Director	15yrs	no data	no data
Alexia Perouse	Independent Director	9yrs	no data	no data

12.0yrs

Average Tenure

Experienced Board: 6W5's board of directors are seasoned and experienced ( 12 years average tenure).

SpineGuard Management

Management criteria checks 2/4

Key information

Recent management updates

SpineGuard SA Announces CFO Changes

Less than half of directors are independent

Less than half of directors are independent

Recent updates

SpineGuard Obtains FDA Clearance for Commercial Release of its PsiFGuard

Spineguard Obtains EC-MDR Certification and Launches Its Threaded Pediguard for Anterior Spine Surgery in Europe

SpineGuard Files Its 510K Dossier in the Us for the Clearance of Its New Smart Drilling Device Dedicated to Sacroiliac Joint Fusion

SpineGuard SA Provides Sales Guidance for the Second Half of 2024

New major risk - Shareholder dilution

Full year 2023 earnings released

New minor risk - Financial data availability

SpineGuard SA to Report Fiscal Year 2023 Results on Apr 17, 2024

New major risk - Market cap size

New major risk - Financial position

First half 2023 earnings released

New major risk - Revenue and earnings growth

SpineGuard Strengthens its Intellectual Property with a New Patent Granted in Brazil

New major risk - Share price stability

SpineGuard SA announced that it expects to receive €7.5 million in funding from Nice & Green SA

SpineGuard SA Announces CFO Changes

Full year 2022 earnings released

SpineGuard SA to Report Fiscal Year 2022 Results on Apr 13, 2023

Less than half of directors are independent

First half 2022 earnings released

Less than half of directors are independent

SpineGuard Obtains FDA Clearance for Commercial Release of Its “Threaded Pediguard” in Anterior Approach Spine Surgery

SpineGuard Files its “510K” Dossier for the Clearance of its “Threaded PediGuard” in Anterior Approach Spine Surgery

First half 2021 earnings released

SpineGuard Announces INMETRO Certification for the 'DSG Connect' in Brazil

Full year 2020 earnings released

SpineGuard SA announced that it expects to receive €9.5 million in funding from Nice & Green SA

SpineGuard SA Obtains FDA Clearance for Commercial Release of Its New “DSG Connect” Platform in the USA

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure